Navigation Links
Cephalon Presents Positive Results for Fentora in Breakthrough Pain,,,Associated with Neuropathic Conditions

All Efficacy Measures Reached Statistical Significance

FRAZER, Pa., May 01, 2007 /PRNewswire-FirstCall/ -- A Cephalon, Inc. Phase 3 clinical trial presented today at the 59th Annual Meeting of the American Academy of Neurology in Boston highlights data demonstrating that FENTORA(R) (fentanyl buccal tablet) [C-II] is beneficial for the treatment of breakthrough pain in patients with neuropathic pain who are already taking opioids around-the clock to manage their persistent pain. This study marks the first time an opioid has been evaluated in patients with breakthrough pain associated with chronic neuropathic pain.

"This study provides strong evidence that opioids like FENTORA may be useful in managing breakthrough pain in patients with chronic neuropathic pain," said Dr. David Simpson, Professor of Neurology at Mount Sinai Medical Center and primary author of this study. "With FENTORA, patients experienced statistically significant and clinically meaningful improvements in pain control and expressed a preference for this medication over the opioid they had previously been prescribed to manage their breakthrough pain."

Breakthrough pain -- a component of chronic pain -- is a flare of moderate-to-severe pain that occurs in the context of controlled persistent pain and is characterized by rapid onset, moderate-to-severe intensity, and relatively short duration. An estimated 74 percent of patients with controlled persistent pain from noncancer chronic pain conditions, including neuropathic pain, will experience breakthrough pain with a median onset of 10 minutes. In this patient population, breakthrough pain episodes can typically last 60 minutes. FENTORA, which is approved for the management of breakthrough pain in patients with cancer who are already taking and who are tolerant to opioids for their underlying persistent cancer pain, is desig
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:9/30/2014)... , Sept. 30, 2014 /PRNewswire/ ... CHDX ) today announced the completion of ... for $24.00 per share in cash.  Healthy Harmony is ... Ltd. ("Fosun") and Ms. Roberta Lipson , the ... merger agreement was adopted by Chindex,s stockholders at a ...
(Date:9/30/2014)... Calif. , Sept. 30, 2014  Allakos ... additional $10 million investment from current investors to ... additional financing was completed following achievement of a ... antibody program, and represents an extension of the ... in December 2012. With this additional financing, Allakos ...
(Date:9/29/2014)... SAN DIEGO , 29 septembre 2014 /PRNewswire/ ... Sankyo) (TSE : 4568) et Ambit Biosciences (NASDAQ : AMBI), ... de fusion définitif en vertu duquel Daiichi Sankyo ... en circulation d,Ambit Biosciences à 15 dollars par ... publique d,achat qui sera suivie d,une fusion avec ...
Breaking Medicine Technology:Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 2Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 3Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 4Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 5Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 2Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 3Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 4Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9
... OMAHA, Neb., May 15 Creighton Medical Laboratories, based ... Omaha, announced today that it has become the first ... effective testing method for cancer. The method, called SNP ... laboratories to study cancer for several years. However, Creighton ...
... , in Damaged Tissue and Cells MANDEVILLE, La., ... leading expert in the field of non-surgical skin rejuvenation ... to speed up the healing process of damaged tissue ... a double-blinded, placebo-controlled clinical study of a glycerin-based bruise-reaction ...
Cached Medicine Technology:Creighton Medical Laboratories First to Offer New Cancer Test 2Creighton Medical Laboratories First to Offer New Cancer Test 3Glycerin Proven to Improve Bruising and Swelling Caused By Trauma to Skin 2
(Date:9/30/2014)... Austin, TX (PRWEB) September 30, 2014 ... for Facial Plastic Surgery, has been approved to be ... of Facial Plastic and Reconstructive Surgery (AAFPRS) fellowship program. ... their meeting in Orlando, Florida. , The Educational and ... throughout the medical community. It represents the finest postgraduate ...
(Date:9/30/2014)... September 30, 2014 Gummy teeth ... gum depigmentation treatments for dark gums. Dark gums are ... people feel extremely self-conscious about their smiles. Dr. Farnoosh ... gums. “I am one of the few dental professionals ... have treated celebrities, business leaders, high-ranking officials and patients ...
(Date:9/30/2014)... HealthDay Reporter TUESDAY, Sept. ... supplements won,t prevent the return of a common type of ... In fact, 64.1 percent of those taking fish oil for ... over the course of 16 months, compared to 63.2 ... did not reduce the twin ills of inflammation or oxidative ...
(Date:9/30/2014)... MYERS, Fla. (PRWEB) September 30, 2014 ... Hospital, is giving breast cancer patients a new, more ... surgeries. , Women who undergo mastectomies, biopsies and lumpectomy ... and promote healing. But after seeing her patients describe ... felt compelled to create a new bra in her ...
(Date:9/30/2014)... New York, New York (PRWEB) September 30, 2014 ... will honor Kenro Izu – founder of the nonprofit, ... City on November 6, 2014, for building a hospital ... sustainable pediatric care. , Izu first encountered Cambodia’s ... suffering from a variety of disabilities and illnesses during ...
Breaking Medicine News(10 mins):Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 2Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 3Health News:Gummy Smile Dentist, Dr. Alex Farnoosh, is Now Offering Gum Depigmentation for Dark Gums 2Health News:Fish Oil Supplements Have Little Effect on Irregular Heartbeat: Study 2Health News:Fish Oil Supplements Have Little Effect on Irregular Heartbeat: Study 3Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 2Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 3Health News:Nobel Prize For Child Advocates Announces 2014 Health Award Honoree 2Health News:Nobel Prize For Child Advocates Announces 2014 Health Award Honoree 3
... WASHINGTON, Sept. 21 Trust for America,s Health ... a new report today featuring a range of evidence-based disease ... reducing costs in communities. , , The ... a summary and examples from an extensive literature review that ...
... , Foundation grants to inspire locally-driven ... PORTLAND, Ore., Sept. 21 The Robert Wood Johnson Foundation ... for Proposal for Partners Investing in Nursing,s Future (PIN), a collaborative ... funding partnerships with local and regional foundations. , ...
... Surgical patients more likely to finish radiation course, study ... and interrupted radiation treatment is a common problem among ... study has found. , Researchers analyzed data from 5,086 ... 1997 and 2003 and found that nearly 40 percent ...
... MD (Sept. 21, 2009) The American Gastroenterological Association ... that the family of the late businessman and photographer, ... a new three-year Research Scholar Award for pancreatic cancer ... Foundation will provide a young investigator with funding and ...
... anyone? Or maybe a big job interview? Dry your palms ... silver lining. Researchers at the Stanford University School of Medicine ... relatively short-term stress can boost the immune system and protect ... this occasional angst seem to last for weeks after the ...
... can blind premature babies are being seen for the first ... Duke University Medical Center. The technology, developed in ... tomography (SD OCT) to create a 3-D picture of the ... way we identify eye conditions in infants," says Cynthia Toth, ...
Cached Medicine News:Health News:New Report Highlights Proven Disease Prevention Programs in Communities 2Health News:New Report Highlights Proven Disease Prevention Programs in Communities 3Health News:New Report Highlights Proven Disease Prevention Programs in Communities 4Health News:Call for Proposals for Partners Investing in Nursing's Future 2Health News:Head, Neck Cancer Treatment Often Not Completed 2Health News:California family honors father with second AGA Foundation Research Scholar Award 2Health News:Short-term stress enhances anti-tumor activity in mice, Stanford study shows 2Health News:Short-term stress enhances anti-tumor activity in mice, Stanford study shows 3Health News:Short-term stress enhances anti-tumor activity in mice, Stanford study shows 4Health News:New device finds early signs of eye disease in preemies 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: